Author:
Nowak Anna K,Lesterhuis W Joost,Kok Peey-Sei,Brown Chris,Hughes Brett GM,Karikios Deme J,John Thomas,Kao Steven C-H,Leslie Connull,Cook Alistair M,Pavlakis Nick,Briscoe Karen,O'Byrne Kenneth J,Karapetis Christos S,Lam Wei-Sen,Langford Ailsa,Yip Sonia,Stockler Martin R
Reference30 articles.
1. Improving quality of life in patients with malignant pleural mesothelioma: results of the randomized pemetrexed + cisplatin vs cisplatin trial using the LCSS-meso instrument;Gralla;Proc Am Soc Clin Oncol,2003
2. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program;Santoro;J Thorac Oncol,2008
3. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial;Zalcman;Lancet,2016
4. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial;Scagliotti;Lancet Respir Med,2019
5. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial;Maio;Lancet Oncol,2017
Cited by
120 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献